The acute monocytic leukemia (THP1) cell model was selected for the production of the CRISPR–Cas9 GSTM1- and/or GSTT1 knockout model, as we have the most patients with a relapsed AML (Supplementary Table 3). The gene discussed is GSTM1; the disease is acute myeloid leukemia.